Hold For Now: Shattuck Labs' SL-172154 Potential In Early Trials (NASDAQ:STTK) | Old North State Wealth News
Connect with us


Hold For Now: Shattuck Labs’ SL-172154 Potential In Early Trials (NASDAQ:STTK)




Shattuck Labs, Inc. (NASDAQ:STTK) developed a proprietary Agonist Redirected Checkpoint [ARC] platform to create bi-functional fusion proteins to treat cancer and autoimmune diseases. STTK’s flagship candidate is SL-172154 in Phase 1 clinical trials for aggressive cancers. These trials leverage the drug’s dual functionality

Read the full article here


Copyright © 2024 ONSWM News. Content posted on the Old North State Wealth News page was developed and produced by a third party news aggregation service. Old North State Wealth Management is not affiliated with the news aggregation service. The information presented is believed to be current. It should not be viewed as personalized investment advice. All expressions of opinion reflect the judgment of the authors on the date the articles were published. The information presented is not an offer to buy or sell, or a solicitation of any offer to buy or sell, any of the securities discussed.